Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Serum Protein Profiling as a Predictor of Gemcitabine Sensitivity in Breast Cancer With Prior Exposure to Anthracyclines and Taxanes

NCT00212069 is registered in ClinicalTrials.gov with National University Hospital, Singapore as lead sponsor.

NCT NCT00212069
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00212069 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Serum Protein Profiling as a Predictor of Gemcitabine Sensitivity in Breast Cancer With Prior Exposure to Anthracyclines and Taxanes
Lead sponsor
National University Hospital, Singapore
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2004
Completion date
April 30, 2013
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer